Towards a cancer mission in Horizon Europe: recommendations.
European healthcare systems
cancer mission
cancer research/care/prevention continuum
comprehensive cancer centres
patient empowerment
science policy
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
29
06
2020
accepted:
01
07
2020
entrez:
5
8
2020
pubmed:
5
8
2020
medline:
1
7
2021
Statut:
ppublish
Résumé
A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research-care-prevention continuum has the potential to achieve in 2030 a 10-year cancer-specific survival for 75% of patients diagnosed in European Union (EU) member states with a well-developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high-quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science-driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC-like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long-term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans-border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence-based advice.
Identifiants
pubmed: 32749074
doi: 10.1002/1878-0261.12763
pmc: PMC7400777
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1589-1615Subventions
Organisme : Foundation ARC
Pays : International
Organisme : German Cancer Aid
Pays : International
Informations de copyright
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
Mol Oncol. 2019 Mar;13(3):549-557
pubmed: 30698321
Mol Oncol. 2020 Jul;14(7):1514-1528
pubmed: 32255249
J Clin Oncol. 2012 Mar 10;30(8):880-7
pubmed: 22312101
JMIR Mhealth Uhealth. 2017 Dec 04;5(12):e187
pubmed: 29203459
Mol Oncol. 2020 Jul;14(7):1577-1585
pubmed: 32463984
Nat Commun. 2020 Feb 14;11(1):896
pubmed: 32060274
Cell. 2017 Jun 1;169(6):1000-1011
pubmed: 28575665
Cell Syst. 2020 Jan 22;10(1):52-65.e7
pubmed: 31668800
Eur J Cancer. 2018 Nov;103:155-159
pubmed: 30241002
Semin Nephrol. 2009 Jul;29(4):435-44
pubmed: 19615564
Nature. 2019 Oct;574(7779):532-537
pubmed: 31645730
BMJ. 2017 Oct 4;359:j4528
pubmed: 28978548
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
CA Cancer J Clin. 2010 Mar-Apr;60(2):120-32
pubmed: 20173172
Science. 2018 Nov 23;362(6417):911-917
pubmed: 30337457
Cancers (Basel). 2020 May 21;12(5):
pubmed: 32455560
Lancet. 2013 Apr 6;381(9873):1224-34
pubmed: 23541056
Mol Oncol. 2019 Mar;13(3):497-501
pubmed: 30811864
Tumori. 2008 Mar-Apr;94(2):164-71
pubmed: 18564602
JAMA Oncol. 2018 Nov 1;4(11):1504-1510
pubmed: 29978189
Eur J Cancer. 2018 Feb;90:34-62
pubmed: 29272783
J Intern Med. 2006 Aug;260(2):103-17
pubmed: 16882274
Science. 2020 Jan 10;367(6474):143-144
pubmed: 31919207
Science. 2015 May 22;348(6237):880-6
pubmed: 25999502
Mol Oncol. 2019 Mar;13(3):636-647
pubmed: 30628161
Nat Med. 2015 Jul;21(7):795-801
pubmed: 26030179
Psychooncology. 2019 Jul;28(7):1362-1366
pubmed: 31106934
Nat Rev Clin Oncol. 2019 May;16(5):312-325
pubmed: 30700859
Cancer Epidemiol. 2015 Dec;39 Suppl 1:S1-10
pubmed: 26164654
Nature. 2019 Oct;574(7779):538-542
pubmed: 31645727
Med Res Rev. 2020 Mar;40(2):586-605
pubmed: 31432544
Mol Oncol. 2014 May;8(3):447-57
pubmed: 24726457
Eur J Cancer. 2015 Jul;51(10):1203-11
pubmed: 25958037
Eur J Cancer. 2018 Nov;104:127-136
pubmed: 30347288
Nat Rev Cancer. 2019 Oct;19(10):553-567
pubmed: 31455893
Psychooncology. 2017 Feb;26(2):144-146
pubmed: 28205357
Mol Oncol. 2019 Mar;13(3):648-652
pubmed: 30677237
Mol Oncol. 2017 Dec;11(12):1661-1672
pubmed: 29024497
Eur J Cancer. 2019 Aug;117:14-31
pubmed: 31229946
Nat Med. 2020 May;26(5):665-671
pubmed: 32405058
Mol Oncol. 2020 Jul;14(7):1529-1537
pubmed: 32112478
Mol Oncol. 2019 Mar;13(3):624-635
pubmed: 30552794
Mol Oncol. 2019 Mar;13(3):567-578
pubmed: 30582778
N Engl J Med. 2010 Aug 19;363(8):733-42
pubmed: 20818875
Bioinformatics. 2018 Sep 1;34(17):i997-i1004
pubmed: 30423075
Mol Oncol. 2019 Mar;13(3):521-527
pubmed: 30657633
Eur J Cancer. 2018 Sep;100:75-84
pubmed: 30014883
Psychooncology. 2018 Apr;27(4):1150-1161
pubmed: 29361206
Genome Med. 2018 Mar 20;10(1):21
pubmed: 29558971
Nature. 2020 Feb;578(7794):266-272
pubmed: 31996850
Mol Oncol. 2020 Jul;14(7):1492-1499
pubmed: 32223048
Oncologist. 2015 Nov;20(11):1326-32
pubmed: 26417037
Mol Oncol. 2015 May;9(5):933-4
pubmed: 25772590
Chin Clin Oncol. 2018 Apr;7(2):15
pubmed: 29764160
Clin Trials. 2019 Jun;16(3):327-328
pubmed: 30895807
Mol Oncol. 2015 May;9(5):967-96
pubmed: 25557400
Mol Oncol. 2019 Mar;13(3):528-534
pubmed: 30667152
Can J Public Health. 2009 Jan-Feb;100(1):Suppl I8-14
pubmed: 19263977
Mol Oncol. 2019 Mar;13(3):653-666
pubmed: 30657631
CA Cancer J Clin. 1999 Mar-Apr;49(2):101-16, 65
pubmed: 11198885
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Mol Oncol. 2018 Nov;12(11):1829-1837
pubmed: 30241109
Eur J Cancer. 2014 Nov;50(16):2745-6
pubmed: 25263570
Mol Oncol. 2019 Mar;13(3):614-618
pubmed: 30628155
Expert Opin Pharmacother. 2017 Oct;18(14):1477-1490
pubmed: 28820000
Nature. 2019 Jan;565(7739):312-317
pubmed: 30602793
Mol Oncol. 2015 May;9(5):940-50
pubmed: 25081646
Eur J Cancer. 2020 Apr;129:41-49
pubmed: 32120274
Hum Genet. 2019 Feb;138(2):109-124
pubmed: 30671672
Mol Oncol. 2019 Mar;13(3):543-548
pubmed: 30628170
Eur J Cancer. 2018 Apr;93:138-139
pubmed: 29454744
Mol Oncol. 2019 Mar;13(3):517-520
pubmed: 30657250
JMIR Mhealth Uhealth. 2019 Aug 27;7(8):e13245
pubmed: 31456578
Mol Oncol. 2019 Mar;13(3):502-510
pubmed: 30657635
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
PLoS One. 2020 Jan 24;15(1):e0227344
pubmed: 31978145
CA Cancer J Clin. 2017 Jan;67(1):65-85
pubmed: 27570942
Nat Rev Clin Oncol. 2020 Mar;17(3):183-194
pubmed: 31619755
BMC Med. 2018 Aug 27;16(1):150
pubmed: 30145981
Science. 2019 Jun 07;364(6444):
pubmed: 31171663
Expert Rev Clin Immunol. 2017 Mar;13(3):235-245
pubmed: 27552944
Palliat Med. 2018 Jan;32(1):69-78
pubmed: 29130418
Science. 2018 Mar 23;359(6382):1350-1355
pubmed: 29567705
Med Clin North Am. 2017 Jul;101(4):787-806
pubmed: 28577627
Nat Rev Cancer. 2019 Jun;19(6):349-358
pubmed: 31024081